Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
THU-472-YI Sorafenib as a second-line treatment after fai... | ResearchHub
Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
THU-472-YI Sorafenib as a second-line treatment after failure of Atezolizumab/Bevacizumab
0
Authors
Francesco Tovoli
21 more
Francesco Tovoli
•
Maria Boe
19 more
•
Fabio Piscaglia
Published
June 1, 2024
Paper
Conversation
0
Reviews
0
Bounties
0
Abstract
Supporters
Support the authors with ResearchCoin
Tip RSC
Journal
Journal of Hepatology
Topics
Medicine
Cancer Oncology
Internal Medicine
Molecular Biology
Sorafenib
Show all topics
DOI
10.1016/s0168-8278(24)01397-7
